Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

If you are looking to invest in top growth stocks, these companies can experience more volatility than the average stock. Here are two top growth stocks to consider buying right now. Eli Lilly (NYSE: ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly (NYSE: LLY) has been in the limelight more frequently of late, with the success of its glucagon-like peptide-1 (GLP-1) drugs that have reinvigorated growth for one of the oldest ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

driven by the success of its glucagon-like peptide-1 (GLP-1) receptor agonist drug portfolio. In the past 12 months, LLY has surged by over 25.6%. In fiscal Q4 2024, Eli Lilly and Company (NYSE ...

Yet the soaring enthusiasm for so-called glucagon-like peptide-1 receptor ... Novo Nordisk and Eli Lilly. All That Glitters Is Not Gold: Issues and Risks Around GLP-1 Medications The effectiveness ...

Eli Lilly makes some of the most powerful weight ... Like Ozempic, the new pill is designed to mimic the glucagon-like peptide 1 hormone that our bodies produce naturally, albeit in very small ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Medications known as glucagon-like peptide 1 (GLP-1 ... Each of these GLP-1 treatments are developed by either Novo Nordisk or Eli Lilly. As I write this, shares of Viking trade for roughly ...